Quantcast

Posts related to ‘MRK’

24/7 Wall St. Closing Bell (DELL, EW, AKS, STLD, BRCM, GMCR, EDMC, NDAQ, QCOM, BZH, BSX, BCO, DO, LEA, MRK, TTWO, VIAB, ZNGA, MNOV, RGDX, BIOS, URG)

All three major US stock indexes opened higher this morning, and spent the rest of the day bouncing around the neutral line. The reports from retailers on same-store sales in ...
Read Full Story »

Merck Close to 52-Week High After Earnings (MRK)

Merck & Company, Inc. (NYSE: MRK) is trading up after its earnings report.  With a high dividend yield of 4.4%, many investors are watching this despite a stance of little ...
Read Full Story »

Top Earnings Previews For Thursday (BZH, PHM, BX, CME, DOW, GNW, GILD, IP, K, MA, MRK, RCL, HOT, TRMB, VRTX, YRCW)

Earnings season is still upon us.  There are going to be many big earnings reports Thursday and we would consider Thursday as the climax for the companies reporting their normal ...
Read Full Story »

Pfizer Sneaks By Earnings Estimates (PFE, MRK)

Pfizer, Inc. (NYSE: PFE) looks good on the surface on its earnings report for the fourth quarter, but the company's guidance may be getting in the way a bit.  The ...
Read Full Story »

Pharma Value Beyond The Patent Expiration Cliff (PFE, MRK, BMY, TEVA, AMGN, GSK)

The tide of patent expirations that is washing over big pharmaceutical houses is cresting now and investors have begun looking forward to how these companies will deal with some sharp ...
Read Full Story »

24/7 Wall St. Closing Bell (COST, XOM, AKAM, P, SCCO, MRK, AYI, CBST, AA, INHX, PSOF, IDIX, NFLX, THRX, LTRX)

US markets opened up slightly this morning and have maintained a slight positive tone for most of the day. Today marks the unofficial beginning of another earnings season, with Alcoa ...
Read Full Story »

Top Analyst Upgrades & Downgrades (AKAM, GAS, AAPL, ARMH, B, COST, XOM, FR, HTH, IART, IGT, MRK, P, PENN, PVH, RBS, SCCO, THOR)

These are some of the top analyst upgrades, downgrades, and initiations seen from Wall Street brokerage and research firms this Monday morning. Akamai Technologies, Inc. (NASDAQ: AKAM) Cut to Sell ...
Read Full Story »

Tracking Dividends in Biotech: Who Follows Amgen in Payouts? (AMGN, PFE, MRK, BIIB, CELG, ALXN, CBST, PDLI, REGN, VRTX)

For several years it has been the case that Amgen Inc. (NASDAQ: AMGN) was considered a biotech though it had at least some of the same problems of Big Pharma players like ...
Read Full Story »

DJIA 2012: Best Targets Imply DJIA 13,678 (BAC, JPM, VZ, IBM, CVX, MCD, CSCO, XOM, GE, HPQ, INTC, MRK, PFE, PG, WMT, DIA)

As each new year replaces the prior year, 24/7 Wall St. looks at the individual targets on all 30 Dow Jones Industrial Average price targets from Wall Street analysts to ...
Read Full Story »

Which Dogs of the Dow Are Best in 2012? (T, VZ, MRK, PFE, GE, DD, JNJ, INTC, PG, MSFT, CVX, JPM, KFT, MCD)

The lineup of the Dogs of the Dow, simply the ten highest dividend yield stocks of the thirty Dow Jones Industrial Average components, appears to be undergoing a bit of ...
Read Full Story »

Get Ready for a Pfizer Dividend Hike… A Holiday Gift From Big Pharma (PFE, MRK, WPI, TEVA)

We recently gave a full review of the DJIA components we expect to raise their dividend payouts in the weeks and months ahead.  Among those we expect to raise the ...
Read Full Story »

Dendreon Raising $125 Million Via I.P. Sale (DNDN, MRK)

Dendreon Corporation (NASDAQ: DNDN) is supposed to be the king of prostate cancer with its PROVENGE treatment.  Unfortunately, PROVENGE sales ran slower than expected after the FDA took forever to ...
Read Full Story »

More DJIA Stocks Set to Hike Dividends Very Soon (DIS, DIA, T, VZ, CSCO, KO, IBM, JNJ, JPM, MMM, PFE, MRK, WMT, DVY, VIG, PFM, HDV)

Dividends are still rising and equity and income investors should expect more of the same for 2012. The Walt Disney Company (NYSE: DIS) joined in on the dividend hike brigade with ...
Read Full Story »

Media Digest (11/23/2011) Reuters, WSJ, FT, Bloomberg

China’s factory activity reaches a 32-month low. (Reuters) Merck (NYSE: MRK) pays $950 million to settle Vioxx charges brought by the government. (Reuters) FCC head wants more examination of the ...
Read Full Story »

Probing for Value in Big Pharmaceutical Stocks (JNJ, PFE, AZN, BMY, MRK)

It now costs about $1 billion to get a new drug to market, or, if a company is unlucky, $1 billion to fail to get the drug to market. Like ...
Read Full Story »